Ascendis Pharma A/S (FRA:A71)
Germany · Delayed Price · Currency is EUR 186.00
+2.00 (1.09%)
At close: Jan 30, 2026
Ascendis Pharma Revenue
Ascendis Pharma had revenue of 213.63M EUR in the quarter ending September 30, 2025, with 269.40% growth. This brings the company's revenue in the last twelve months to 646.55M, up 97.46% year-over-year. In the year 2024, Ascendis Pharma had annual revenue of 363.64M with 36.34% growth.
Revenue (ttm)
646.55M
Revenue Growth
+97.46%
P/S Ratio
18.07
Revenue / Employee
635.74K
Employees
1,017
Market Cap
11.68B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 363.64M | 96.92M | 36.34% |
| Dec 31, 2023 | 266.72M | 215.54M | 421.20% |
| Jan 1, 2023 | 51.17M | 43.40M | 557.93% |
| Dec 31, 2021 | 7.78M | 825.00K | 11.87% |
| Dec 31, 2020 | 6.95M | -6.42M | -48.01% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mainova AG | 3.89B |
| Gelsenwasser AG | 3.36B |
| Paul Hartmann AG | 2.44B |
| Lechwerke AG | 1.06B |
| tonies SE | 510.38M |
| Maschinenfabrik Berthold Hermle AG | 469.42M |
| EUROKAI GmbH & Co. KGaA | 262.47M |
| Northern Data AG | 200.27M |
Ascendis Pharma News
- 18 days ago - Ascendis Pharma (ASND) Surges 3.0%: Is This an Indication of Further Gains? - Nasdaq
- 19 days ago - Ascendis Pharma A/S at JPMorgan Healthcare Conference Transcript - GuruFocus
- 19 days ago - Ascendis Pharma A/S (ASND) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 22 days ago - Ascendis Pharma (ASND) Focuses on Core Plans Amidst Market Conditions - GuruFocus
- 22 days ago - Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 23 days ago - Ascendis Pharma (ASND) Receives Increased Price Target from Wells Fargo | ASND Stock News - GuruFocus
- 23 days ago - Ascendis Confirms Durable Growth Benefits In Achondroplasia In COACH Trial - Nasdaq
- 23 days ago - Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP and Growth Hormone in Achondroplasia Transcript - Seeking Alpha